Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.

Nemoto A, Saida S, Kato I, Kikuchi J, Furukawa Y, Maeda Y, Akahane K, Honna-Oshiro H, Goi K, Kagami K, Kimura S, Sato Y, Okabe S, Niwa A, Watanabe K, Nakahata T, Heike T, Sugita K, Inukai T.

Mol Cancer Ther. 2016 Jan;15(1):94-105. doi: 10.1158/1535-7163.MCT-14-1065. Epub 2015 Dec 4.

2.

Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.

Nemoto A, Inukai T, Uno K, Kiyokawa N, Miyagawa Y, Takahashi K, Sato H, Akahane K, Hirose K, Honna-Oshiro H, Goi K, Kagami K, Nakazawa S, Fujimoto J, Inaba T, Sugita K.

Leuk Res. 2013 Jan;37(1):93-101. doi: 10.1016/j.leukres.2012.10.001. Epub 2012 Oct 23.

PMID:
23099235
3.

Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.

Zhang X, Inukai T, Hirose K, Akahane K, Kuroda I, Honna-Oshiro H, Kagami K, Goi K, Nakamura K, Kobayashi M, Endo M, Yagita H, Kurosawa H, Thomas Look A, Honda H, Inaba T, Nakazawa S, Sugita K.

Leukemia. 2012 Dec;26(12):2483-93. doi: 10.1038/leu.2012.139. Epub 2012 May 30.

PMID:
22743623
4.

BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.

Kuroda I, Inukai T, Zhang X, Kikuchi J, Furukawa Y, Nemoto A, Akahane K, Hirose K, Honna-Oshiro H, Goi K, Kagami K, Yagita H, Tauchi T, Maeda Y, Sugita K.

Oncogene. 2013 Mar 28;32(13):1670-81. doi: 10.1038/onc.2012.186. Epub 2012 Jun 4.

PMID:
22665066

Supplemental Content

Loading ...
Support Center